Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Elucidating the molecular pathology of DEPDC5 mutation induced mTOR-hyperactivation associated with epilepsy and autism spectrum disorder

ABSTRACT: Elucidating the molecular pathology of DEPDC5 mutation induced mTOR-hyperactivation associated with epilepsy and autism spectrum disorder

PROVIDER: PRJNA1003403 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Elucidating the molecular pathology of DEPDC5 mutation induced mTOR-hyperactivation associated with epilepsy and autism spectrum disorder

Project description:To observe the effects of DEPDC5-KO on the transcriptome, 3‟-mRNA analysis was performed

2024-12-31 | GSE240337 | GEO

Genetics of Epilepsy and Cognitive Disorders: Autism Spectrum Disorders Study

Project description:Genetics of Epilepsy and Cognitive Disorders: Autism Spectrum Disorders Study

| PRJNA213481 | ENA

Epilepsy in a melanocyte-lineage mTOR hyperactivation mouse model: A novel epilepsy model.

Project description:ObjectiveTo clarify the complex mechanism underlying epileptogeneis, a novel animal model was generated.MethodsIn our previous research, we have generated a melanocyte-lineage mTOR hyperactivation mouse model (Mitf-M-Cre Tsc2 KO mice; cKO mice) to investigate mTOR pathway in melanogenesis regulation, markedly reduced skin pigmentation was observed. Very unexpectedly, spontaneous recurrent epilepsy was also developed in this mouse model.ResultsCompared with control littermates, no change was found in either brain size or brain mass in cKO mice. Hematoxylin staining revealed no obvious aberrant histologic features in the whole brains of cKO mice. Histoimmunofluorescence staining and electron microscopy examination revealed markedly increased mTOR signaling and hyperproliferation of mitochondria in cKO mice, especially in the hippocampus. Furthermore, rapamycin treatment reversed these abnormalities.ConclusionsThis study suggests that our melanocyte-lineage mTOR hyperactivation mouse is a novel animal model of epilepsy, which may promote the progress of both epilepsy and neurophysiology research.

| S-EPMC6980560 | biostudies-literature

90 min Met4 hyperactivation ChIP-chip

Project description:Identification of in vivo binding targets of Met4 and Met32 by conducting chromatin immunoprecipitation studies using genomic tiling arrays (ChIP-on-chip 4X44K whole yeast genome arrays by Agilent) following 90 minutes Met4 hyperactivation.

2012-02-21 | E-MEXP-3302 | biostudies-arrayexpress

Rat model of MTLE: Animals with epilepsy vs animals without epilepsy

Project description:This SuperSeries is composed of the following subset Series: GSE27015: Rat model of MTLE: Animals with epilepsy vs animals without epilepsy (Agilent) GSE27166: Rat model of MTLE: Animals with epilepsy vs animals without epilepsy (codelink) Refer to individual Series

2011-02-13 | E-GEOD-27268 | biostudies-arrayexpress

Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy

2012-07-18 | GSE39447 | GEO

Epilepsy Genetics Initiative

Project description:Epilepsy Genetics Initiative

| PRJNA434482 | ENA

Epilepsy Genetics Initiative

Project description:Epilepsy Genetics Initiative

| PRJNA434483 | ENA

mTOR, a Potential Target to Treat Autism Spectrum Disorder.

Project description:Mammalian target of rapamycin (mTOR) is a key regulator in various cellular processes, including cell growth, gene expression, and synaptic functions. Autism spectrum disorder (ASD) is frequently accompanied by monogenic disorders, such as tuberous sclerosis complex, phosphatase and tensin homolog tumor hamartoma syndrome, neurofibromatosis 1, and fragile X syndrome, in which mTOR is hyperactive. Mutations in the genes involved in the mTOR-mediated signaling pathway have been identified in some cases of syndromic ASD. Evidences indicate a pathogenic role for hyperactive mTOR-mediated signaling in ASD associated with these monogenic disorders, and mTOR inhibitors are a potential pharmacotherapy for ASD. Abnormal synaptic transmission through metabotropic glutamate receptor 5 may underlie in a part of ASD associated with hyperactive mTOR-mediated signaling. In this review, the relationship between mTOR and ASD is discussed.

| S-EPMC5070418 | biostudies-literature

Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy

Project description:Autism is present in 1% of the population, yet treatments are extremely limited. We identified homozygous inactivating mutations in the BCKDK gene in families presenting with autism and epilepsy. The encoded branched chain ketoacid dehydrogenase kinase protein is responsible for phosphorylation-mediated inactivation of the E1-alpha subunit of branched chain ketoacid dehydrogenase, itself mutated in Maple Syrup Urine Disease (MSUD). Patients with homozygous BCKDK mutations display reductions in BCKDK mRNA and protein, E1-alpha phosphorylation and serum branched chain amino acids (BCAAs). Bckdk knockout mice show abnormal brain amino acids profiles and neurobehavioral defects, which are largely corrected by dietary BCAA supplementation. Thus autism presenting with epilepsy due to BCKDK mutations represent a new and potentially treatable disease. A 51 chip study that includes both human and mouse samples to investigate the expression changes that result in a mutation or knockout of the BCKDK gene. Starting with human fibroblasts from three affecteds and two controls, cells were converted into IPSs, then NPCs, and finally Neurons. Each of these cell types were used to view the expression changes between a cells with a BCKDK mutation versus controls. Finally, a mouse knockout was performed to verify consistency of the expression pattern differences between the BCKCK knockout and wild-type. Samples are labeled as Affected if the sample came from a patient with a BCKDK mutation and WildType otherwise. Samples were usually replicated once.

2012-07-17 | E-GEOD-39447 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data